American Cannabis Companies See More Revenue Than Canadian LPs
After a historic 2020, cannabis is ticking off even more milestones in 2021.
And we may be in store for the most transformative cannabis environment in decades.
This year, Virginia legalized adult-use through legislative measures. Now, this market won’t go live until 2024, but it brings the total number of states that have greenlit adult-use to 16, with 36 that allow for medical use.
This creates a very interesting situation, as Canada and Mexico have both legalized cannabis at a federal level. So the U.S. is the only country in North America yet to do so.
But that could soon change.
Congress has promised to introduce measures to end cannabis prohibition in 2021. And last week, the Secure and Fair Enforcement (SAFE) Banking Act was reintroduced. This would allow the cannabis industry to have access to the financial systems every other industry enjoys.
The bill easily passed the U.S. House of Representatives in 2019. But it was stonewalled in the Senate.
However, the writing is clearly on the wall. Currently, 47 states, four U.S. territories and the District of Columbia – representing 97.7% of the U.S. population – have legalized or decriminalized cannabis in some form or another.
I’ve already outlined that I think we’ll see changes in Europe this year regarding cannabis. And I definitely believe a major change is in store for the U.S.
With those enormous opportunities on the horizon, let’s take a look at cannabis companies by revenue and valuation.
The Six Sisters of Cannabis
I like to point out that there are way more cryptocurrencies than there are publicly traded cannabis companies.
This highlights how nascent the industry still is. And in all likelihood, as merger and acquisition activity picks up speed once again, the number of publicly traded cannabis companies will dwindle.
Now, the Canadian licensed producers (LPs) – Aphria (Nasdaq: APHA), Aurora Cannabis (NYSE: ACB), Canopy Growth Corp. (Nasdaq: CGC), Cronos Group (Nasdaq: CRON), Tilray (Nasdaq: TLRY) and others – are often the most familiar to investors. That’s because these companies trade on major U.S. exchanges (the New York Stock Exchange and the Nasdaq) since cannabis is legal at the federal level in their home country.
They’re not violating any listing regulations by participating in “illegal” activities. This is also why they don’t operate in the U.S.
But I’ve pointed out for years that these Canadian LPs aren’t the biggest moneymakers in the industry… at least, not yet.
In fact, when we rank cannabis companies by quarterly revenue, we notice two things right off the bat.
First, Canopy is the only Canadian LP in the top five companies, in terms of quarterly revenue.
The top four spots go to Curaleaf Holdings (OTC: CURLF), Green Thumb Industries (OTC: GTBIF), Trulieve Cannabis (OTC: TCNNF) and Cresco Labs (OTC: CRLBF). Each of these American multistate operators (MSOs) is reporting more than $160 million in revenue per quarter. (Though the figure for Cresco is its forecast – it will report final numbers this week.)
And of the top 10 cannabis companies by quarterly revenue, only three are Canadian LPs – Canopy, Aphria and Aurora.
Second, there’s a steep step-down in revenue after the top five. The club of companies with $100 million-plus in quarterly revenue is quite small.
I consider these the “cannabis majors” – similar to what we have in the crude oil industry. I would also include the merger between Aphria and Tilray in the major category.
For now, I think after those top six, we’re going to see companies establish regional dominance.
Let’s be realistic… Not every MSO can be a Curaleaf, Cresco, Green Thumb or Trulieve. And not every Canadian LP can be a Canopy or Aphria/Tilray.
Though, that doesn’t mean they can’t be profitable or good investments.
Fortunately, the U.S. market is large enough to support multiple majors as well as smaller regional players (which will be gobbled up over time, in my opinion).
And on the international stage, there will be a race for these six majors to divvy up markets. Here, the Canadian LPs currently have an early, first-mover advantage. However, Curaleaf recently made a big splash in Europe (anticipating a change at the federal level).
Are Cannabis Shares Too Expensive?
Now let’s address a question I’m asked quite often: What’s overvalued in the cannabis space?
In young, rapidly growing markets – like cannabis – investors tend to pay a nice premium for shares. The focus is on future growth, not current revenue.
With that in mind, when we look at the cannabis companies listed above and their current price-to-sales (P/S) ratios, we again see an interesting trend.
Canopy has the highest P/S ratio by a wide margin. Though, this is far below the 100-plus P/S ratios we saw for shares in 2018.
But many, from Columbia Care (OTC: CCHWF) to Green Thumb, trade in roughly the same range.
Aphria is the midpoint.
And there is some value, in terms of not only majors, like Cresco, but also MSOs, like Ayr Wellness (OTC: AYRWF), Harvest Health & Recreation (OTC: HRVSF) and even MedMen Enterprises (OTC: MMNFF).
The U.S. cannabis industry is likely to see a major change this year. And we can already see changes taking place around the world. Revenue is surging for the sector – particularly in American MSOs.
But the upside here is we’re not seeing the manic, sky-high valuations of 2017 and 2018. There are bargains to be had.
That makes cannabis a sector to be embraced.
Here’s to high returns,
3 Major Roadblocks for Cannabis Companies
May 3, 2021